AbCellera Biologics (HAM:8QQ) Net Income From Continuing Operations : €-135.58 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. AbCellera Biologics's net income from continuing operations for the three months ended in Mar. 2024 was €-37.36 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €-135.58 Mil.

AbCellera Biologics Net Income From Continuing Operations Historical Data

The historical data trend for AbCellera Biologics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Net Income From Continuing Operations Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-1.99

97.75

135.82

149.64

-134.25

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-37.46	-28.18	-26.81	-43.24	-37.36

AbCellera Biologics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-135.58 Mil.

AbCellera Biologics (HAM:8QQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (HAM:8QQ) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ABCL:USA 8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (HAM:8QQ) Headlines

No Headlines